Incivo: second hepatitis C protease inhibitor launched

Incivo (telaprevir) is a new oral preparation licensed in combination with peginterferon alfa and ribavirin for the treatment of hepatitis C in both pretreated and treatment-naive adults.

Telaprevir is taken every 8 hours with food
Telaprevir is taken every 8 hours with food

PHARMACOLOGY

Telaprevir is a direct inhibitor of NS3 protease, which is required by the hepatitis C virus for replication.1

CLINICAL STUDIES

Telaprevir has been investigated in 2 studies in treatment-naïve patients (ADVANCE and ILLUMINATE) and 1 study in patients previously treated with peginterferon and ribavirin (REALIZE). Patients received telaprevir, in combination with peginterferon alfa and ribavirin, for 8 or 12 weeks followed by 12–24 weeks of peginterferon alfa and ribavirin alone, depending on virological response. In all studies, patients who received telaprevir had a significantly higher rate of sustained virological response at 24 weeks after last planned dose of study drug.2–4

REFERENCES

  1. Incivo Summary of Product Characteristics, 2011.
  2. Jacobson IM et al. N Engl J Med 2011; 364(25): 2405-16.
  3. Sherman KE et al. N Engl J Med 2011; 365(11): 1014-24.
  4. Zeuzeum S et al. N Engl J Med 2011; 364(25): 2417-28.

View Incivo drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more